Tag Archives: Andrew Fein

Deciphera Pharmaceuticals (DCPH) Received its Third Buy in a Row

After JMP Securities and Guggenheim gave Deciphera Pharmaceuticals (NASDAQ: DCPH) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Andrew Fein maintained a Buy rating on Deciphera Pharmaceuticals today and set a price

ACADIA Pharmaceuticals Inc (ACAD) Gets a Buy Rating from H.C. Wainwright

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on ACADIA Pharmaceuticals Inc (ACAD – Research Report), with a price target of $60.00. The company’s shares closed last Monday at $42.41, close to its 52-week

H.C. Wainwright Sticks to Their Hold Rating for United Therapeutics (UTHR)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Hold rating on United Therapeutics (UTHR – Research Report), with a price target of $85.00. The company’s shares closed last Monday at $89.84. According to TipRanks.com, Fein is

H.C. Wainwright Keeps a Buy Rating on Catalyst Pharma (CPRX)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report), with a price target of $9.00. The company’s shares closed last Monday at $4.96. According to TipRanks.com, Fein is

Analysts Offer Insights on Healthcare Companies: BioCryst (NASDAQ: BCRX) and Cardiovascular Systems (NASDAQ: CSII)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioCryst (BCRX – Research Report) and Cardiovascular Systems (CSII – Research Report). BioCryst (BCRX) H.C. Wainwright analyst Andrew Fein reiterated a Buy rating

Seattle Genetics (SGEN) Receives a Buy from H.C. Wainwright

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Seattle Genetics (SGEN – Research Report), with a price target of $140.00. The company’s shares closed last Monday at $100.89, close to its 52-week high